Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Mar 24, 2020
Genentech Announces FDA approval of Clinical Trial for Chugai’s Actemra for COVID-19 Pneumonia
TOKYO, March 24, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Genentech issued a press release on March 23 (local time) regarding the FDA approval of a clinical trial for Actemra®, a humanized anti-human IL-6 receptor monoclonal antibody [generic name: tocilizumab (genetical recombination)] created by Chugai, for the treatment of hospitalized patients with severe COVID-19 pneumonia.
Please refer to the link below for details of the press release:
- Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia
- https://www.gene.com/media/press-releases/14843/2020-03-23/genentech-announces-fda-approval-of-clin
[Note]
Roche Announces the Initiation of a Clinical Study of Chugai’s Actemra for the Treatment of COVID-19 (A press release issued on March 19, 2020)
https://www.chugai-pharm.co.jp/english/news/detail/20200319154500_709.html
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Toshiya Sasai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
